|

Tislelizumab: 200mg, intravenous infusion, Q3W Clinical Trials

1 actively recruiting trial

Top Sponsors

  • Sir Run Run Shaw Hospital1

Indications

  • Liver Disease1
  • Liver Cancer1
  • Hepatocellular Carcinoma1
  • Cancer1

Other1 trial

Study on the Therapeutic Effect of Different Infusion Times of Tislelizumab on Postoperative High-risk Hepatocellular Carcinoma
N/A

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.